Abstract:Background Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy. Methods We developed a costimulation method for expansion of Vδ2 T cells in PBMCs by activating γδ T-cell receptor (γδTCR) and Toll-like receptor (TLR) 7/8 using isopentenyl pyrophosphate (IPP) and resiquimod, respectively, and tested the functional markers and antitumoral effects in vitro two-dimensional two-dimensional and three-dimensional spheroid models and in vivo models. Single-cell sequencing dataset analysis and reverse-phase protein array were employed for mechanistic studies. Results We find that Vδ2 T cells expanded by IPP plus resiquimod showed significantly increased cytotoxicity to tumor cells with lower programmed cell death protein 1 (PD-1) expression than Vδ2 T cells expanded by IPP or ZOL. Mechanistically, the costimulation enhanced the activation of the phosphatidylinositol 3-kinase (PI3K)–protein kinase B (PKB/Akt)–the mammalian target of rapamycin (mTOR) pathway and the TLR7/8–MyD88 pathway. Resiquimod stimulated Vδ2 T-cell expansion in both antigen presenting cell dependent and independent manners. In addition, resiquimod decreased the number of adherent inhibitory antigen-presenting cells (APCs) and suppressed the inhibitory function of APCs by decreasing PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in these cells during in vitro Vδ2 T-cell expansion. Finally, we showed that human Vδ2 T cells can be expanded from PBMCs and spleen of humanized NSG mice using IPP plus resiquimod or ZOL, demonstrating that humanized mice are a promising preclinical model for studying human γδ T-cell development and function. Conclusions Vδ2 T cells expanded by IPP and resiquimod demonstrate improved anti-tumor function and have the potential to increase the efficacy of γδ T cell-based therapies.

Mtor Inhibition Potentiates Cytotoxicity of Vγ4 Γδ T Cells Via Up-Regulating NKG2D and TNF-α

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function

Compensatory Increase of Transglutaminase 2 is Responsible for Resistance to Mtor Inhibitor Treatment

Roles of Mtorc1 and Mtorc2 in Controlling Γδ T1 and Γδ T17 Differentiation and Function

Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Prediction and Optimization of the Therapeutic Effect of Mtor Inhibitors in Aggressive B-Cell Lymphomas

Mtor-Mediated Glycolysis Contributes to the Enhanced Suppressive Function of Murine Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells

Mtor Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer

The Mechanistic Target of Rapamycin Complex 1 Pathway Contributes to the Anti-Tumor Effect of Granulocyte-Macrophage-Colony-Stimulating Factor-Producing T Helper Cells in Mouse Colorectal Cancer

Inhibition of Mtorc1 Signaling Sensitizes Hepatocellular Carcinoma Cells to Glycolytic Stress

Amino acids and RagD potentiate mTORC1 activation in CD8 + T cells to confer antitumor immunity

CGP57380 Enhances Efficacy of RAD001 in Non-Small Cell Lung Cancer Through Abrogating Mtor Inhibition-Induced Phosphorylation of Eif4e and Activating Mitochondrial Apoptotic Pathway.

Synthetic Lethality of Combined Glutaminase and Hsp90 Inhibition in Mtorc1-Driven Tumor Cells

Mtor Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD.

Mtor Signaling Disruption from Myeloid-Derived Suppressive Cells Protects Against Immune-Mediated Hepatic Injury Through the HIF1α-dependent Glycolytic Pathway.

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.

MiR-15a/16 Deficiency Enhances Anti-Tumor Immunity of Glioma-Infiltrating CD8+ T Cells Through Targeting Mtor.

Inhibition of 4EBP Phosphorylation Mediates the Cytotoxic Effect of Mechanistic Target of Rapamycin Kinase Inhibitors in Aggressive B-cell Lymphomas

CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment

Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors